bluebird bio, Inc.
NASDAQ:BLUE
Overview | Financials
Company Name | bluebird bio, Inc. |
Symbol | BLUE |
Currency | USD |
Price | 0.487 |
Market Cap | 93,768,983 |
Dividend Yield | 0% |
52-week-range | 0.45 - 5.53 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Andrew Obenshain |
Website | https://www.bluebirdbio.com |
An error occurred while fetching data.
About bluebird bio, Inc.
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy.
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD